Diversey's Oxivir 1 gets C. Auris claim for Oxivir 1

Written by Staff | June 19, 2019 | Print  |

In a recent press release, Diversey announced that the Environmental Protection Agency (EPA) has approved the addition of Candida auris (C. auris) to the master label of Oxivir® 1, in both its ready-to-use and wipes formats.

Oxivir 1 is effective against C. auris and a broad spectrum of pathogens in just 1 minute.

 Oxivir 1 is the first non-bleach disinfectant specifically approved as effective against C. auris by the EPA. The EPA recognizes that C. auris is a serious public health threat, particularly in healthcare settings, and until now, there have been no EPA-approved products specifically registered to control C. auris. Oxivir 1 products have now been tested and passed EPA’s review to secure registration of this emerging, and difficult-to-kill pathogen. This applies to both RTU and Wipes, EPA registration Nos. 70627-74 and 70627-77, respectively.

Click here to continue>>

 

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.